GlassScriptPhysician profile
John D Gelles
NPI 1952743627
$37,057.98
in general payments reported to CMS, 2019-2025
28 companies · $3,000 in 2025
The $3,000 reported for 2025 was more than what 95% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,264 · 2020: $4,051 · 2021: $9,257 · 2022: $8,089 · 2023: $5,441 · 2024: $2,957 · 2025: $3,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,000 · Food and Beverage: $2,326 · Gift: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,000.00 |
| Food and Beverage | $2,325.64 |
| Gift | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oculus, INC. | $15,840.15 | 2021-2025 | Pentacam Axl Wave, Myopia Master, Pentacam |
| Glaukos Corporation | $7,107.35 | 2019-2025 | Photrexa, Photrexa Viscous and Photrexa |
| Visionary Optics LLC | $4,872.00 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $3,763.44 | 2019-2020 | |
| Coopervision INC. | $1,633.98 | 2021-2025 | Onefit Contact Lens |
| Alcon Vision LLC | $1,398.99 | 2019 | |
| Sun Pharmaceutical Industries INC. | $310.07 | 2020-2025 | Cequa |
| Sight Sciences, INC. | $307.51 | 2019-2025 | Tearcare System |
| Lumenis Be INC | $264.96 | 2025 | Optilight |
| Kala Pharmaceuticals, INC. | $181.41 | 2021-2022 | |
| Oyster Point Pharma, INC. | $179.43 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $175.86 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $158.85 | 2025 | Cirrus Hd-Oct |
| Topcon Healthcare, INC. | $141.34 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $121.93 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $91.86 | 2019-2021 | |
| Harrow Eye, LLC | $78.16 | 2024-2025 | Vevye |
| Dompe US, INC. | $74.52 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $56.40 | 2024-2025 | Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $51.84 | 2022-2024 | Acthar |
| Beaver-Visitec International, INC. | $48.08 | 2021 | |
| Ocular Therapeutix, INC. | $42.98 | 2019 | |
| Biotissue Holdings INC. | $41.32 | 2024-2025 | |
| Eyevance Pharmaceuticals LLC | $34.73 | 2022 | |
| Shire North American Group INC | $25.93 | 2019 | |
| Rxsight INC | $24.04 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Alimera Sciences, INC. | $16.99 | 2024 | Yutiq, Iluvien |
| Mallinckrodt Enterprises LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gelles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.